Freeman CL, Pararajalingam P, Jin L, Balasubramanian S, et al. Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial. Leukemia 2022 Aug 13. pii: 10.1038/s41375-022-01658.
PMID: 35963941